AstraZeneca
AZN
64,04 €
Share price
2.99%
Change (1 day)
-11.61%
Change (1 year)
Categories
Revenue for AstraZeneca (AZN)
Revenue in 2025 (TTM): €51.10 Billion
According to AstraZeneca's latest financial reports the company's current revenue (TTM 
) is €47.59 Billion. In 2024 the company made a revenue of €51.96 Billion an increase over the revenue in the year 2023 that were of €41.44 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AstraZeneca from 1996 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | €51.10 B | -1.66% |
| 2024 | €51.96 B | 25.39% |
| 2023 | €41.44 B | 0.23% |
| 2022 | €41.34 B | 25.14% |
| 2021 | €33.03 B | 52.68% |
| 2020 | €21.64 B | -0.58% |
| 2019 | €21.76 B | 12.73% |
| 2018 | €19.30 B | 3.13% |
| 2017 | €18.72 B | -14.38% |
| 2016 | €21.86 B | -3.23% |
| 2015 | €22.59 B | 3.66% |
| 2014 | €21.80 B | 17.1% |
| 2013 | €18.61 B | -11.96% |
| 2012 | €21.14 B | -18.24% |
| 2011 | €25.86 B | 3.41% |
| 2010 | €25.01 B | 9.24% |
| 2009 | €22.89 B | 1.29% |
| 2008 | €22.60 B | 11.66% |
| 2007 | €20.24 B | 0.9% |
| 2006 | €20.06 B | -0.76% |
| 2005 | €20.21 B | 28% |
| 2004 | €15.79 B | 5.5% |
| 2003 | €14.97 B | -11.31% |
| 2002 | €16.88 B | -36.65% |
| 2001 | €26.64 B | 38.57% |
| 2000 | €19.23 B | 4.96% |
| 1999 | €18.32 B | 121.27% |
| 1998 | €8.27 B | 9.72% |
| 1997 | €7.54 B | -21.63% |
| 1996 | €9.63 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Bristol-Myers Squibb BMY | €41.23 B | -13.36% | 🇺🇸 USA |
 Pfizer PFE | €54.06 B | 13.61% | 🇺🇸 USA |
 Merck MRK | €55.33 B | 16.26% | 🇺🇸 USA |
 GlaxoSmithKline GSK | €35.13 B | -26.18% | 🇬🇧 UK |
 Sanofi SNY | €41.02 B | -13.79% | 🇫🇷 France |
 Eli Lilly LLY | €42.41 B | -10.87% | 🇺🇸 USA |
 Johnson & Johnson JNJ | €77.32 B | 62.47% | 🇺🇸 USA |
 Abbott Laboratories ABT | €36.65 B | -22.99% | 🇺🇸 USA |
 Biogen BIIB | €8.49 B | -82.15% | 🇺🇸 USA |
 Novartis NVS | €46.06 B | -3.20% | 🇨🇭 Switzerland |